MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
U.S. Futures Drop as Trump Issues Iran Military Deadline, Oil Prices Jump 
U.S. Dollar Climbs as Trump Escalates Rhetoric Against Iran 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Trump's FY2027 Budget: Major Defense Boost and Domestic Spending Cuts 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Gold Prices Drop as Trump Escalates Iran Threats, Oil Surges 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
India's Services Sector Growth Slows to 14-Month Low in March Amid Rising Costs 
Japan's Services Sector Growth Slows in March Amid Rising Middle East Tensions 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
China's Energy Resilience Shields Economy From Global Oil Shock, Goldman Sachs Says 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
